Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy


Continuous renal replacement therapies (CRRT) such as continuous venovenous hemofiltration are used to provide renal support for critically ill patients with acute kidney injury (AKI), particularly patients who are hemodynamically unstable. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how CRRT affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, Cefiderocol, in critically ill patient receiving CRRT.

Full Title of Study: “Effect of Continuous Renal Replacement Therapy and Residual Renal Clearance on Cefiderocol Pharmacokinetics in Critically Ill Adult Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2023

Detailed Description

This is a prospective, multi-center, open-label, Phase 1b, pharmacokinetic study of Cefiderocol in 16 critically ill patients receiving CRRT support. Informed consent will be collected from all study participants, legal authorized representative, or their next of kin in order to participate. This is not a treatment study; all participants will receive standard of care antibiotics which may include cefiderocol as necessary to treat any current infection.


  • Drug: Cefiderocol
    • After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol

Arms, Groups and Cohorts

  • Experimental: Cefiderocol
    • Participants will receive four to six doses of Cefiderocol as per current prescribing information based on effluent rate

Clinical Trial Outcome Measures

Primary Measures

  • Cefiderocol concentration
    • Time Frame: 8 to 12 hours
    • The total and free plasma concentration of cefiderocol over time
  • Cefiderocol clearance
    • Time Frame: 8 to 12 hours
    • The Clearance in liters/hour of Cefiderocol from the plasma
  • Cefiderocol maximum concentration
    • Time Frame: 8 to 12 hours
    • The maximum concentration of Cefiderocol from the plasma

Participating in This Clinical Trial

Inclusion Criteria

1. Age 18 years or older; 2. Receiving CRRT including CVVH, CVVHD, and CVVHDF support. Exclusion Criteria:

1. Females who are pregnant or breast-feeding; 2. History of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibiotic (a history of mild rash to a cephalosporin followed by uneventful re-exposure is not a contraindication); 3. A hemoglobin less than 8 gm/dl at baseline; 4. Acute liver injury, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal, or AST or ALT > 3 times the upper limit of normal with an associated total bilirubin > 2 times upper limit of normal; 5. Any rapidly-progressing disease or immediately life-threatening illness (defined as imminent death within 48 hours in the opinion of the investigator); 6. Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of study data.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 120 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hartford Hospital
  • Collaborator
    • Shionogi Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Tomefa Asempa, Associate Director, Clinical and Translational Infectious Diseases Research – Hartford Hospital
  • Overall Contact(s)
    • Tomefa Asempa, PharmD, 8609721109, Tomefa.asempa@hhchealth.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.